Regulatory Roundup: FDA Issues Final Guidance to Amend IND Reporting Requirements - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Issues Final Guidance to Amend IND Reporting Requirements

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a final guidance for sponsors and investigators regarding its enforcement of the agency’s final rule, “Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans.” The rule amended IND reporting requirements under 21 CFR part 312 and added safety reporting requirements for persons conducting bioavailability and bioequivalence studies under 21 CFR part 320, states the guidance. The final rule was released in September 2010 and took effect in March 2011. Enforcement of the reporting requirements outlined in the final rule will begin on Sept. 28, 2011. The final guidance replaces the draft guidance that was issued with the rule in September 2010.

The Pharmaceutical Inspection Cooperation Scheme (PIC/S) celebrated its 40th anniversary on May 31, 2011, in Geneva, Switzerland. More than 160 individuals, including FDA Commissioner Margaret Hamburg, from around the world participated in the event. FDA’s participation was unique as it symbolized its recently accepted membership to the cooperation scheme. Also new to PIC/S is the Ukraine State Inspectorate. PIC/S is a global collaboration representing 39 competent authorities and focuses on GMP inspections of pharmaceutical manufacturing sites. PIC/S also works with the European Commission and has partnership agreements with regulatory and global health bodies such as EMA, EDQM, UNICEF, and WHO, and works with industry and academic groups globally on training programs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here